Shidlovski/iStock via Getty Images 4D Molecular Therapeutics ( NASDAQ: FDMT ) is down ~30% in Wednesday morning trading after releasing interim phase 2 results for 4D-150 in wet age-related macular degeneration. The 24-week data was from the Population Extension cohort of the PRISM trial. The company billed the results as positive, noting that improvement in best corrected visual acuity (BCVA) of 4.
2 letters from baseline to week 24 was achieved at the planned phase 3 dose of 3E10 vg/eye. 4DMT also said that there was no significant anterior chamber inflammation or vitreous inflammation events in any of the 30 patients in the 3E10 arm. Also, in the 3E10 dose, there was an 89% reduction in mean annualized injection rate.
More on 4D Molecular Therapeutics 4D Molecular Therapeutics: Catalysts With Pioneering Gene Therapy With Directed Evolution Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics Historical earnings data for 4D Molecular Therapeutics Financial information for 4D Molecular Therapeutics.
